Company: PSTV
Filing Date: 2025-04-01
Form Type: PRER14A
Source: 0001140361-25-011649
Chunk: 34

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-01
Form: PRER14A
Chunk 34
---
='center'>**PROPOSAL 4: APPROVAL OF THE EXTENSION OF THE TERM OF THE SERIES B WARRANTS**</div>

### Background and Overview
On May 9, 2024, the Company issued in a private placement (the “May Offering”) to certain accredited investors, including certain of our executive officers and directors, among other securities, Series B common stock purchase warrants (the “May 2024 Warrants”) to purchase shares of Common Stock. On February 13, 2025, the Company consummated the previously announced transaction pursuant to that certain securities purchase and exchange agreement (the “SPEA”) with investors in the May Offering other than those of our executive officers and directors who had participated in the May Offering. As a requirement to enter into the SPEA, the Outside Investors required the Company to agree to extend the term of the May 2024 Warrants to five years from the original issue date of those warrants, or May 9, 2029, subject to stockholder approval. The initial exercise price of the May 2024 Warrants ranges from $1.772 to $1.908.

#### Why We are Seeking Approval of this Proposal
The SPEA requires the Company to hold a meeting of stockholders by no later than May 30, 2025 for the purpose of obtaining approval with respect to the extension of the term of the May 2024 Warrants to May 9, 2029, including to ensure compliance with Nasdaq Listing Rule 5635(d), which provides that stockholder approval is required prior to the issuance of securities in a transaction, other than a public offering, involving the sale, issuance or potential issuance by the Company of Common Stock (or securities convertible into or exercisable for Common Stock), which equals 20% or more of the Common Stock or 20% or more of the voting power outstanding before the issuance, at a price less than the lower of: (i) the closing price immediately preceding the signing of the binding agreement, or (ii) the average closing price of the Common Stock for the five trading days immediately preceding the signing of the binding agreement for the transaction.

#### Potential Effects of Approval of this Proposal
If approved, this Proposal No. 4 could result in the issuance of shares of Common Stock upon the exercise of the May 2024 Warrants subject to their respective beneficial ownership limitations during a period not initially contemplated upon initial issue.

Upon issuance of shares of Common Stock upon the exercise of the May